We are live on ! Find out more
CMPX icon

Compass Therapeutics
CMPX

79 hedge funds and large institutions have $170M invested in Compass Therapeutics in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more capital invested

Capital invested by funds: $93.4M → $170M (+$76.2M)

53% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 19

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.49% less ownership

Funds ownership: 67.49% → 67% (-0.49%)

4% less funds holding

Funds holding: 82 → 79 (-3)

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

Holders
79
Holders Change
-3
Holders Change %
-3.66%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
11
Increased
29
Reduced
19
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Blackstone Inc
Blackstone Inc
New York
+$2.91M
2
TCM
Tang Capital Management
California
+$2.26M
3
MB
MPM BioImpact
Massachusetts
+$794K
4
Morgan Stanley
Morgan Stanley
New York
+$262K
5
BlackRock
BlackRock
New York
+$258K

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$4.2M
2
CAM
Cormorant Asset Management
Massachusetts
-$2.03M
3
Millennium Management
Millennium Management
New York
-$329K
4
Citadel Advisors
Citadel Advisors
Florida
-$254K
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$244K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$41.1M – – –
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$20.5M – – –
Blackstone Inc
3
Blackstone Inc
New York
$18.4M +$2.91M +2,333,590 +30%
BlackRock
4
BlackRock
New York
$12.5M +$258K +206,815 +3%
MB
5
MPM BioImpact
Massachusetts
$10.4M +$794K +636,808 +13%
RSCM
6
Rock Springs Capital Management
Maryland
$10.4M +$144K +115,451 +2%
Vanguard Group
7
Vanguard Group
Pennsylvania
$7.88M +$113K +90,657 +2%
Fidelity Investments
8
Fidelity Investments
Massachusetts
$7.61M +$7.35K +5,898 +0.1%
VC
9
Vivo Capital
California
$6.54M – – –
BOCH
10
Blue Owl Capital Holdings
New York
$5.3M +$62.3K +50,000 +2%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$4.25M +$23.8K +19,095 +0.8%
State Street
12
State Street
Massachusetts
$3.43M +$4.75K +3,808 +0.2%
Janus Henderson Group
13
Janus Henderson Group
United Kingdom
$3.36M -$4.2M -3,373,056 -65%
TCM
14
Tang Capital Management
California
$3.34M +$2.26M +1,812,995 New
BBA
15
Baker Bros. Advisors
New York
$2.87M – – –
Northern Trust
16
Northern Trust
Illinois
$1.55M +$121K +96,825 +13%
MIM
17
Monashee Investment Management
Massachusetts
$920K – – –
Morgan Stanley
18
Morgan Stanley
New York
$695K +$262K +209,971 +125%
Goldman Sachs
19
Goldman Sachs
New York
$683K +$169K +135,623 +58%
CM
20
CM Management
Florida
$570K – – –
N
21
Nuveen
North Carolina
$560K – – –
Charles Schwab
22
Charles Schwab
California
$527K – – –
Connor, Clark & Lunn Investment Management (CC&L)
23
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$427K +$653 +524 +0.2%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$427K -$64.8K -52,004 -18%
Renaissance Technologies
25
Renaissance Technologies
New York
$410K +$102K +82,000 +58%
1
2 3 4

CMPX Hedge Fund Activity: Q3 2024 in Review

79 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q3 2024, worth a combined $170M — up 82% from $93.4M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CMPX and 11 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 29 added.

The largest buyer was Blackstone Inc, adding an estimated $2.91M. The largest seller was Janus Henderson Group, cutting an estimated $4.2M.

  • 79 institutional investors held Compass Therapeutics (CMPX) as of Q3 2024, down from 82 in Q2 2024.
  • Funds reported $170M of Compass Therapeutics stock for Q3 2024, up 82% quarter-over-quarter.
  • 11 funds opened new Compass Therapeutics positions in Q3 2024 and 14 closed out, a net change of -3 holders.
  • The largest Compass Therapeutics buyer in Q3 2024 was Blackstone Inc, an estimated $2.91M added.
  • The largest Compass Therapeutics seller in Q3 2024 was Janus Henderson Group, an estimated $4.2M sold.

Based on aggregated 13F filings for Q3 2024.